Maraviroc for Previously Treated Patients with R5 HIV-1 Infection | Zendy

Roy M. Gulick | Zendy; Jacob Lalezari | Zendy; James Goodrich | Zendy; Nathan Clumeck | Zendy; Edwin DeJesus | Zendy; Andrzej Horban | Zendy; Jeffrey P. Nadler | Zendy; Bonaventura Clotet | Zendy; Anders Karlsson | Zendy; Michael Wohlfeiler | Zendy; John B Montana | Zendy; Mary McHale | Zendy; John F. Sullivan | Zendy; Caroline E. Ridgway | Zendy; Steve Felstead | Zendy; Michael W. Dunne | Zendy; Elna van der Ryst | Zendy; Howard Mayer | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Maraviroc for Previously Treated Patients with R5 HIV-1 Infection

Author(s) -

Roy M. Gulick,

Jacob Lalezari,

James Goodrich,

Nathan Clumeck,

Edwin DeJesus,

Andrzej Horban,

Jeffrey P. Nadler,

Bonaventura Clotet,

Anders Karlsson,

Michael Wohlfeiler,

John B Montana,

Mary McHale,

John F. Sullivan,

Caroline E. Ridgway,

Steve Felstead,

Michael W. Dunne,

Elna van der Ryst,

Howard Mayer

Publication year - 2008

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa0803152

Subject(s) - maraviroc , medicine , placebo , ccr5 receptor antagonist , viral load , drug resistance , drug , human immunodeficiency virus (hiv) , virology , pharmacology , microbiology and biotechnology , alternative medicine , chemokine , receptor , pathology , chemokine receptor , biology

CC chemokine receptor 5 antagonists are a new class of antiretroviral agents.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research